Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Advanced Malignancy. According to GlobalData, Phase I drugs for Advanced Malignancy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Adebrelimab LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Adebrelimab overview
Adebrelimab (Ariely) is a humanized anti PD-L1 monoclonal antibody, acts as an anti-neoplastic agent. It is formulated as solution for intravenous route of administration. Ariely is indicated for the treatment of small cell lung cancer.
Adebrelimab (SHR-1316) is under development for the treatment of advanced malignancy, solid tumors including advanced HR +/HER2 negative invasive breast cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma, small cell lung cancer, adenocarcinoma of the gastroesophageal junction and gastric cancer, esophageal squamous cell cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, pancreatic cancer, metastatic pancreatic cancer, intrahepatic cholangiocarcinoma, cervical cancer and non-small cell lung carcinoma. The drug candidate is administered through intravenous route. The drug candidate is a humanized IgG4 monoclonal antibody that acts by targeting PD-L1.
Jiangsu Hengrui Medicine overview
Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
For a complete picture of Adebrelimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
